In the first phase 3 trial of a RET inhibitor as adjuvant therapy, selpercatinib markedly improved event-free survival vs placebo in early-stage RET fusion-positive NSCLC.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25?src=rss
Author :
Publish date : 2026-05-31 12:20:00
Copyright for syndicated content belongs to the linked Source.
